Literature DB >> 19442000

Parasagittal osteotomy for en bloc resection of multilevel cervical chordomas.

Dean Chou1, Frank Acosta, Jordan M Cloyd, Christopher P Ames.   

Abstract

En bloc resection of chordoma has been shown to be critical for prolonging long-term survival and disease-free intervals in patients. Cervical spine chordomas pose special challenges because of the vertebral arteries and critical nerve roots involved. Multilevel chordomas pose even greater challenges because of the need to remove multiple segments of the spine in 1 piece without tumor violation. Although there have been 2 case reports describing multilevel spondylectomy for cervical chordoma, to the authors' knowledge, there are no reports of parasagittal osteotomies for en bloc resection of multilevel cervical chordomas. The use of these osteotomies allows us to avoid intralesional resection and adhere to the oncological principle of en bloc tumor excision. The authors report their management of 3 multilevel cervical chordomas and describe their technique of en bloc tumor removal using parasagittal osteotomy.

Entities:  

Mesh:

Year:  2009        PMID: 19442000     DOI: 10.3171/2009.2.SPINE08472

Source DB:  PubMed          Journal:  J Neurosurg Spine        ISSN: 1547-5646


  3 in total

1.  En bloc resection of a C2-C3 upper cervical chordoma: Technical note.

Authors:  Alexander G Weil; Mohammed Shehadeh; Tareck Ayad; Olivier Abboud; Daniel Shedid
Journal:  Surg Neurol Int       Date:  2015-11-25

2.  Sacral Chordoma with Bilateral Inguinal Lymph Node Metastasis and Metachronous Tumor of the Clivus: A Case Report.

Authors:  Manal Ms Elghareeb; Mona Yy Abd Allah; Sieza S Abdallah; Ahmed R Eldesoky; Amal Af Halim
Journal:  J Orthop Case Rep       Date:  2021-05

Review 3.  Total spondylectomy of recurrent giant cell tumors in the cervical spine: Two case reports and review of literature.

Authors:  Ji Tu; Wentian Li; Shenglei Shu; Yukun Zhang; Wenbin Hua; Shuai Li; Shuhua Yang; Cao Yang
Journal:  Medicine (Baltimore)       Date:  2018-05       Impact factor: 1.889

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.